Zai Lab Starts Trial of Anti-PD1 Antibody for Endometrial Cancer

Shanghai 's Zai Lab has dosed the first patient in a China Phase Ib trial of retifanlimab, an anti-PD1 antibody. The trial is a China arm of the global POD1UM-101 study, which tests retifanlimab as a monotherapy in patients with previously treated, microsatellite instability-high endometrial cancer. In 2019, Zai announced a $77.5 million collaboration with Incyte to develop retifanlimab in Greater China. More details.... Stock Symbols: (NSDQ: ZLAB; HK: 9688) (NSDQ: INCY) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.